Sofinnova Ventures
Latest statistics and disclosures from Sofinnova Investments's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NTRA, VERA, GMAB, JAZZ, RAPP, and represent 42.35% of Sofinnova Investments's stock portfolio.
- Added to shares of these 10 stocks: GMAB (+$91M), Seaport Therapeutics (+$77M), GILD (+$43M), ANAB (+$17M), ISRG (+$16M), GMED (+$16M), NRIX (+$13M), DSGN (+$13M), TRAX (+$11M), ABT (+$11M).
- Started 13 new stock positions in SGMT, ISRG, TRAX, ABSI, AKTS, DSGN, GILD, HTFL, NRIX, GMED. ABT, SION, Seaport Therapeutics.
- Reduced shares in these 10 stocks: IWM (-$149M), , AZN (-$90M), UTHR (-$89M), QQQ (-$87M), IBB (-$80M), CELC (-$76M), BMY (-$64M), AXSM (-$62M), JAZZ (-$56M).
- Sold out of its positions in ACAD, AXGN, BIIB, BBIO, CELC, CMPX, CYTK, DXCM, HRMY, QQQ.
- Sofinnova Investments was a net seller of stock by $-998M.
- Sofinnova Investments has $1.9B in assets under management (AUM), dropping by -26.49%.
- Central Index Key (CIK): 0001631134
Tip: Access up to 7 years of quarterly data
Positions held by Sofinnova Ventures consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sofinnova Investments
Sofinnova Investments holds 56 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Natera (NTRA) | 21.8 | $421M | 1.6M | 271.45 |
|
|
| Vera Therapeutics Cl A (VERA) | 6.2 | $120M | 2.8M | 42.91 |
|
|
| Genmab A/S Sponsored Ads (GMAB) | 5.7 | $111M | +437% | 4.0M | 27.47 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 4.6 | $88M | -38% | 365k | 240.97 |
|
| Rapport Therapeutics (RAPP) | 4.1 | $79M | 1.9M | 41.67 |
|
|
| Seaport Therapeutics | 4.0 | $77M | NEW | 3.6M | 21.72 |
|
| Ultragenyx Pharmaceutical (RARE) | 3.8 | $74M | -36% | 2.2M | 33.39 |
|
| Arrivent Biopharma (AVBP) | 3.0 | $59M | 1.7M | 34.74 |
|
|
| Bioage Labs (BIOA) | 2.9 | $56M | 2.3M | 24.51 |
|
|
| Bristol Myers Squibb (BMY) | 2.6 | $51M | -55% | 877k | 57.62 |
|
| Supernus Pharmaceuticals (SUPN) | 2.5 | $48M | +8% | 1.0M | 46.51 |
|
| Rhythm Pharmaceuticals (RYTM) | 2.3 | $45M | -9% | 408k | 111.03 |
|
| Gilead Sciences (GILD) | 2.2 | $43M | NEW | 343k | 126.34 |
|
| United Therapeutics Corporation (UTHR) | 2.1 | $41M | -68% | 77k | 541.83 |
|
| Cogent Biosciences (COGT) | 2.1 | $40M | -51% | 1.0M | 38.70 |
|
| Axsome Therapeutics (AXSM) | 2.0 | $39M | -61% | 160k | 244.77 |
|
| Immatics SHS (IMTX) | 1.9 | $37M | 3.7M | 10.13 |
|
|
| Dyne Therapeutics (DYN) | 1.9 | $37M | 1.7M | 22.21 |
|
|
| Immunome (IMNM) | 1.9 | $37M | 1.7M | 21.19 |
|
|
| Ideaya Biosciences (IDYA) | 1.8 | $35M | -18% | 925k | 37.27 |
|
| Anaptysbio Inc Common (ANAB) | 1.7 | $33M | +98% | 494k | 67.50 |
|
| Nektar Therapeutics Com New (NKTR) | 1.7 | $33M | -7% | 472k | 69.81 |
|
| Pharvaris N V (PHVS) | 1.6 | $31M | +7% | 881k | 34.58 |
|
| Arcus Biosciences Incorporated (RCUS) | 1.5 | $29M | +2% | 946k | 30.83 |
|
| Inhibrx Biosciences (INBX) | 1.5 | $29M | -25% | 303k | 94.75 |
|
| BioMarin Pharmaceutical (BMRN) | 1.1 | $21M | -54% | 359k | 57.22 |
|
| Veradermics Common Stock (MANE) | 0.9 | $18M | +103% | 149k | 122.94 |
|
| Alcon Ord Shs (ALC) | 0.9 | $17M | -64% | 256k | 67.10 |
|
| Insmed Com Par $.01 (INSM) | 0.9 | $17M | -54% | 158k | 106.62 |
|
| Intuitive Surgical Com New Call Option (ISRG) | 0.8 | $16M | NEW | 40k | 397.68 |
|
| Globus Med Cl A Call Option (GMED) | 0.8 | $16M | NEW | 200k | 79.01 |
|
| Edgewise Therapeutics (EWTX) | 0.8 | $16M | 381k | 40.63 |
|
|
| Exelixis Put Option (EXEL) | 0.7 | $14M | 254k | 54.41 |
|
|
| Nurix Therapeutics (NRIX) | 0.7 | $13M | NEW | 524k | 24.26 |
|
| Design Therapeutics (DSGN) | 0.6 | $13M | NEW | 865k | 14.47 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.6 | $12M | -25% | 256k | 47.04 |
|
| First Tracks Biotherapeutics Ord Shs (TRAX) | 0.6 | $11M | NEW | 565k | 20.12 |
|
| Abbott Laboratories (ABT) | 0.6 | $11M | NEW | 123k | 90.74 |
|
| Disc Medicine (IRON) | 0.6 | $11M | +86% | 146k | 73.14 |
|
| Tenax Therapeutics Com New (TENX) | 0.4 | $7.3M | +378% | 500k | 14.55 |
|
| Sionna Therapeutics (SION) | 0.3 | $6.4M | NEW | 144k | 43.99 |
|
| Absci Corp (ABSI) | 0.2 | $3.9M | NEW | 337k | 11.59 |
|
| Mirum Pharmaceuticals (MIRM) | 0.2 | $3.2M | 28k | 117.07 |
|
|
| Jade Biosciences (JBIO) | 0.1 | $2.4M | 107k | 22.22 |
|
|
| Savara (SVRA) | 0.1 | $2.2M | 365k | 6.16 |
|
|
| Praxis Precision Medicines I Com New (PRAX) | 0.1 | $2.2M | -89% | 6.4k | 334.79 |
|
| Septerna (SEPN) | 0.1 | $1.6M | 48k | 33.49 |
|
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.1 | $1.5M | +127% | 322k | 4.56 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $1.3M | NEW | 167k | 7.73 |
|
| Wave Life Sciences SHS (WVE) | 0.1 | $1.1M | 189k | 5.81 |
|
|
| Aktis Oncology (AKTS) | 0.1 | $1.0M | NEW | 32k | 32.23 |
|
| Tyra Biosciences (TYRA) | 0.1 | $1.0M | -84% | 32k | 31.94 |
|
| Bolt Biotherapeutics (BOLT) | 0.0 | $530k | 138k | 3.85 |
|
|
| Nextcure (NXTC) | 0.0 | $356k | 223k | 1.60 |
|
|
| Imagenebio (IMA) | 0.0 | $188k | 32k | 5.90 |
|
|
| Heartflow Inc/Sh (HTFL) | 0.0 | $149k | NEW | 5.1k | 29.34 |
|
Past Filings by Sofinnova Investments
SEC 13F filings are viewable for Sofinnova Investments going back to 2018
- Sofinnova Investments 2026 Q2 filed Aug. 14, 2026
- Sofinnova Investments 2026 Q1 filed May 15, 2026
- Sofinnova Investments 2025 Q4 filed Feb. 13, 2026
- Sofinnova Investments 2025 Q3 filed Nov. 14, 2025
- Sofinnova Investments 2025 Q2 filed Aug. 14, 2025
- Sofinnova Investments 2025 Q1 filed May 15, 2025
- Sofinnova Investments 2024 Q4 filed Feb. 14, 2025
- Sofinnova Investments 2024 Q3 filed Nov. 13, 2024
- Sofinnova Investments 2023 Q4 restated filed Aug. 15, 2024
- Sofinnova Investments 2024 Q1 restated filed Aug. 14, 2024
- Sofinnova Investments 2024 Q2 filed Aug. 9, 2024
- Sofinnova Investments 2024 Q1 filed May 15, 2024
- Sofinnova Investments 2023 Q3 filed Nov. 14, 2023
- Sofinnova Investments 2023 Q2 filed Aug. 14, 2023
- Sofinnova Investments 2023 Q1 filed May 11, 2023
- Sofinnova Investments 2022 Q4 filed Feb. 14, 2023